Jim Cramer said on CNBC that Johnson & Johnson illustrates the performance of defensive stocks as investors move away from artificial intelligence-related shares. Over the past month, healthcare and consumer staples gained 7% and 6%, respectively, while the S&P 500 fell nearly 3% and technology stocks dropped more than 9%. Johnson & Johnson’s shares rose 20% since a position was initiated in early April and reached a record high before reversing lower during a difficult trading session. The company also announced the acquisition of Ollin Biosciences for $2.2 billion, plus up to $1.13 billion in potential milestone payments, to strengthen its portfolio of treatments for serious eye diseases.
Source: Read the original article


